Pay in 4 interest-free payments of $5.29 Learn more
Ships within 48 hours · Estimated delivery Oct 30 - Nov 4
Patients should evaluate treatment protocols alongside pricing considerations when selecting their healthcare partners
It is not listed in the FDA's Orange Book, and no Investigational New Drug (IND) application for BPC-157 has been publicly disclosed
MOTS-c targets AMPK-dependent insulin sensitization Regulatory status / FDA lists both peptides among bulk drug substances under evaluation for compounding Why No Direct Comparison Exists Neither AOD-9604 nor MOTS-c has advanced far enough in clinical development for a randomized head-to-head trial
Both require subcutaneous injection
Supplementary information Supplementary Tables 1 and 2 (download XLSX Supplementary Table 1
US$ 22.69
US$ 21.13
US$ 21.74
